Reps. Brian Higgins (D–NY), Brett Guthrie (R–KY), Doris Matsui (D–CA), and Gus Bilirakis (R–FL) announced introduction of the Cancer Drug Parity Act, a bipartisan bill requiring health insurance plans that cover intravenous and injectable cancer medications to also cover orally administered cancer medications at the equivalent rate.
On Aug. 26, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
